Gilgamesh Pharmaceuticals
Jonathan Sporn is a Former Harvard and NIH Scientist and a Drug developer in neurology and psychiatry at J&J Pfizer. Jonathan is a Sr Director in R&D and Business Development (Lyrica, Pristiq) and a Sole Founder of Perception Neuroscience exited to ATAI (invested $100k and the estimated value of $70-100M).
Gilgamesh Pharmaceuticals
Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy.